S. Viatte u. a.: Reverse immunology approach for the identification of CD8 T-cell-defined antigens: Advantages and hurdles. In: Immunology and Cell Biology, 84, 2006, S. 318–330. PMID 16681829doi:10.1111/j.1440-1711.2006.01447.x (Review)
M. Schirle u. a.: Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. In: Eur J Immunol, 30, 2000, S. 2216–2225. PMID 10940913
S. Viatte u. a.: Reverse immunology approach for the identification of CD8 T-cell-defined antigens: Advantages and hurdles. In: Immunology and Cell Biology, 84, 2006, S. 318–330. PMID 16681829doi:10.1111/j.1440-1711.2006.01447.x (Review)
M Nielsen, C Lundegaard, T Blicher, K Lamberth, M Harndahl, S Justesen, G Roeder, B Peters, A Sette, O Lund, S. Buus: NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PMID 17726526
K. Falk u. a.: Allelespecific motifs revealed by sequencing of self-peptides eluted from MHC molecules. In: Nature, 351, 1991, S. 290–296. PMID 1709722
K. C. Parker u. a.: Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. In: J Immunol, 152, 1994, S. 163–175. PMID 8254189
J. Hammer u. a.: Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. In: J Exp Med, 180, 1994, S. 2353–2358. PMID 7964508
H. G. Rammensee u. a.: Towards patient-specific tumor antigen selection for vaccination. In: Immunol Rev, 188, 2002, S. 164–176. PMID 12445290